期刊文献+

莫西沙星治疗艾滋病合并下呼吸道感染的临床观察 被引量:2

Clinical Observation of Moxifloxacin in the Treatment of Acquired Immunodeficiency Syndrome Complicated with Lower Respiratory Tract Infection
下载PDF
导出
摘要 目的探讨莫西沙星治疗敏感菌引起的艾滋病合并下呼吸道感染的疗效。方法将184例艾滋病合并下呼吸道感染患者随机分成两组,治疗组(n=94)予莫西沙星静脉滴注,对照组(n=90)予盐酸左氧氟沙星静脉滴注,疗程均为7~12 d。结果两组治疗效果比较差异有统计学意义(P<0.05)。细菌清除率:治疗组92.3%,对照组88.5%,两组比较差异无统计学意义(P>0.05);不良反应发生率:治疗组4.3%,对照组5.6%,两组比较差异无统计学意义(P>0.05)。结论莫西沙星治疗艾滋病合并下呼吸道感染疗效确切,安全性好。 Objective To evaluate the efficacy and safety of moxifloxacin therapy in the treatment of patients with acquired immunodeficiency syndrome(AIDS)complicated with lower respiratory tract infection.Methods 184 patients with AIDS complicated with lower respiratory tract Infection were randomly divided into two groups.In treatment group(n=94),moxifloxacin was administered by intravenous infusion.In control group(n=90),levofloxacin was administered by intravenous infusion.The total treatment duration was 7~12 days.Results There was statistically significant difference(P0.05)in treatment effectiveness.The bacterial clearance rates were 92.3% in treatment group,88.5% in control group.There was no significant difference(P0.05).The incidence of adverse drug reactions of two groups were 4.3% in treatment group and 5.6% in control group,respectively.There was no significant difference(P0.05).Conclusion moxifloxacin intravenous infusion in the treatment of AIDS complicated with lower respiratory tract infection was more effective and safe.
作者 李洪智
出处 《医学综述》 2011年第5期796-797,共2页 Medical Recapitulate
关键词 莫西沙星 艾滋病 下呼吸道感染 临床观察 Moxifloxacin Acquired immunodeficiency syndrome Lower Respiratory Tract Infection Clinical observation
  • 相关文献

参考文献3

二级参考文献30

  • 1Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
  • 2Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545.
  • 3Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301.
  • 4Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754.
  • 5Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408.
  • 6National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing.Pennsylvania:NCCLS,2002.M100-S12.
  • 7Statement 1996 CA-SFM Zone sizes and MIC breakpoints for non-fastidious organisms.Clin Microbiol Infect,1996,2 Suppl 1:S46.
  • 8Morosini MI,Canton R,Loza E,et al.In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.Antimicrob Agents Chemother,2001,45:2427-2431.
  • 9Sutcliffe J,Grebe T,Tait-Kamradt A,et al.Detection of erythromycin-resistant determinants by PCR.Antimicrob Agents Chemother,1996,40:2562-2566.
  • 10Kataja J,Huovinen P,Skurnik M,et al.Erythromycin resistance genes in group A streptococci in Finland.The Finnish Study Group for Antimicrobial Resistance.Antimicrob Agents Chemother,1999,43:48-52.

共引文献883

同被引文献13

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部